Which has higher valuation and earnings, FLNA or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is FLNA or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Immuneering N/A -31.93% -29.92%

Which has higher valuation & earnings, FLNA or ZNTL?

Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.73 N/A

Is FLNA or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Which has stronger earnings & valuation, FLNA or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is FLNA or NVCT more profitable?

Cassava Sciences' return on equity of -53.90% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Nuvectis Pharma N/A -161.00% -98.88%

Cassava Sciences (FLNA) Competitors

$1.21 -0.01 (-0.82%)

As of 04:00 PM Eastern

Compare

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Immuneering (IMRX), Zentalis Pharmaceuticals (ZNTL), Editas Medicine (EDIT), Nuvectis Pharma (NVCT), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Immuneering?

Cassava Sciences (NASDAQ:FLNA) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Immuneering's return on equity of -31.93% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Immuneering	N/A	-31.93%	-29.92%

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Immuneering had 6 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for Immuneering and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Immuneering's score of 0.64 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
Immuneering	Positive

Cassava Sciences has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Cassava Sciences presently has a consensus price target of $5.00, indicating a potential upside of 313.22%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 274.15%. Given Cassava Sciences' higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Immuneering beats Cassava Sciences on 11 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Cassava Sciences (NASDAQ:FLNA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

In the previous week, Zentalis Pharmaceuticals' average media sentiment score of 1.89 beat Cassava Sciences' score of 0.93 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Zentalis Pharmaceuticals	Very Positive

Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A

38.1% of Cassava Sciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cassava Sciences has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 313.22%. Zentalis Pharmaceuticals has a consensus target price of $5.83, indicating a potential upside of 61.14%. Given Cassava Sciences' higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Cassava Sciences beats Zentalis Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Cassava Sciences has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$38.69M	6.45	-$160.06M	-$1.23	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Editas Medicine has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

In the previous week, Cassava Sciences' average media sentiment score of 0.93 beat Editas Medicine's score of 0.43 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Editas Medicine	Neutral
Cassava Sciences	Positive

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 111.76%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 313.22%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cassava Sciences has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Cassava Sciences' return on equity of -53.90% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Cassava Sciences	N/A	-53.90%	-34.20%

Summary

Cassava Sciences beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Nuvectis Pharma?

Cassava Sciences (NASDAQ:FLNA) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Cassava Sciences' return on equity of -53.90% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, Nuvectis Pharma had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Cassava Sciences. Nuvectis Pharma's average media sentiment score of 1.31 beat Cassava Sciences' score of 0.93 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Positive
Nuvectis Pharma	Positive

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 313.22%. Nuvectis Pharma has a consensus target price of $13.00, indicating a potential upside of 3.26%. Given Cassava Sciences' higher possible upside, equities analysts plainly believe Cassava Sciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nuvectis Pharma beats Cassava Sciences on 7 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to MacroGenics?

Cassava Sciences (NASDAQ:FLNA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 313.22%. MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 38.89%. Given Cassava Sciences' higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, MacroGenics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat MacroGenics' score of 0.63 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
MacroGenics	Positive

Cassava Sciences has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Cassava Sciences' return on equity of -53.90% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
MacroGenics	-44.79%	-147.80%	-28.40%

Cassava Sciences has a beta of -0.71, suggesting that its share price is 171% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

MacroGenics has higher revenue and earnings than Cassava Sciences. MacroGenics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
MacroGenics	$149.50M	1.68	-$74.62M	-$1.10	N/A

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MacroGenics beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.46M	$2.96B	$6.42B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.64%
P/E Ratio	-0.75	18.71	24.56	24.10
Price / Sales	N/A	312.98	492.34	88.92
Price / Cash	N/A	56.59	44.13	56.69
Price / Book	0.79	4.04	10.61	6.64
Net Income	-$90.97M	$75.79M	$3.57B	$337.89M
7 Day Performance	-8.33%	2.54%	1.56%	1.73%
1 Month Performance	2.54%	0.11%	2.08%	3.16%
1 Year Performance	-41.55%	24.52%	27.77%	29.83%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.6812 of 5 stars	$1.21 -0.8%	$5.00 +313.2%	-40.5%	$58.46M	N/A	N/A	20
IMRX Immuneering	2.6406 of 5 stars	$4.12 -3.6%	$16.50 +301.0%	+73.0%	$266.89M	N/A	N/A	60
ZNTL Zentalis Pharmaceuticals	2.339 of 5 stars	$3.70 +1.1%	$5.83 +57.7%	+133.1%	$263.74M	N/A	N/A	160
EDIT Editas Medicine	3.0115 of 5 stars	$2.65 -2.4%	$5.40 +104.2%	+9.3%	$259.94M	$38.69M	N/A	230	Short Interest Increase
NVCT Nuvectis Pharma	0.9226 of 5 stars	$9.55 +0.1%	$10.00 +4.7%	+38.2%	$253.36M	N/A	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

How does Cassava Sciences compare to Immuneering?

Summary

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Summary

How does Cassava Sciences compare to Editas Medicine?

Summary

How does Cassava Sciences compare to Nuvectis Pharma?

Summary

How does Cassava Sciences compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. IMRX, ZNTL, EDIT, NVCT, and MGNX

How does Cassava Sciences compare to Immuneering?

Is FLNA or IMRX more profitable?

Do insiders & institutionals believe in FLNA or IMRX?

Does the media prefer FLNA or IMRX?

Which has more volatility and risk, FLNA or IMRX?

Do analysts rate FLNA or IMRX?

Which has higher valuation and earnings, FLNA or IMRX?

Summary

How does Cassava Sciences compare to Zentalis Pharmaceuticals?

Is FLNA or ZNTL more profitable?

Does the media refer more to FLNA or ZNTL?

Which has higher valuation & earnings, FLNA or ZNTL?

Do institutionals & insiders have more ownership in FLNA or ZNTL?

Which has more risk & volatility, FLNA or ZNTL?

Do analysts recommend FLNA or ZNTL?

Summary

How does Cassava Sciences compare to Editas Medicine?

Which has preferable earnings and valuation, EDIT or FLNA?

Which has more risk and volatility, EDIT or FLNA?

Does the media refer more to EDIT or FLNA?

Do institutionals & insiders hold more shares of EDIT or FLNA?

Do analysts prefer EDIT or FLNA?

Is EDIT or FLNA more profitable?

Summary

How does Cassava Sciences compare to Nuvectis Pharma?

Which has more volatility and risk, FLNA or NVCT?

Is FLNA or NVCT more profitable?

Does the media prefer FLNA or NVCT?

Which has stronger earnings & valuation, FLNA or NVCT?

Do institutionals and insiders believe in FLNA or NVCT?

Do analysts recommend FLNA or NVCT?

Summary

How does Cassava Sciences compare to MacroGenics?

Do analysts prefer FLNA or MGNX?

Does the media prefer FLNA or MGNX?

Is FLNA or MGNX more profitable?

Which has more volatility & risk, FLNA or MGNX?

Which has stronger earnings & valuation, FLNA or MGNX?

Do insiders and institutionals have more ownership in FLNA or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools